235,112 Shares in Precigen, Inc. $PGEN Acquired by Inspire Investing LLC

Key Points

• Inspire Investing LLC recently acquired 235,112 shares of Precigen, Inc. ($PGEN), valued at approximately $350,000, indicating a growing interest from institutional investors.
• Precigen's stock has seen fluctuations, with a 1-year high of $5.22 and a current trading value around $3.79, reflecting an 8.5% decrease in recent trading.
• Analysts have a generally positive outlook on Precigen, with four analysts issuing a Buy rating and a consensus price target of $8.25 for the stock.

Inspire Investing LLC acquired a new position in Precigen, Inc. (NASDAQ:PGEN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 235,112 shares of the biotechnology company's stock, valued at approximately $350,000. Inspire Investing LLC owned about 0.08% of Precigen as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MetLife Investment Management LLC purchased a new stake in shares of Precigen in the first quarter worth approximately $124,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Precigen by 3.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock worth $16,801,000 after purchasing an additional 410,595 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Precigen in the first quarter worth approximately $275,000. Mill Creek Capital Advisors LLC raised its stake in shares of Precigen by 131.8% in the first quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company's stock worth $380,000 after purchasing an additional 145,000 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Precigen by 26.6% in the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 10,900 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Nancy H. Agee acquired 15,360 shares of Precigen stock in a transaction on Tuesday, August 19th. The stock was acquired at an average cost of $3.20 per share, with a total value of $49,152.00. Following the completion of the acquisition, the director owned 192,196 shares in the company, valued at approximately $615,027.20. This trade represents a 8.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 41,005 shares of company stock worth $167,651 over the last three months. 47.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on PGEN shares. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Citigroup reissued an "outperform" rating on shares of Precigen in a research note on Tuesday, August 19th. HC Wainwright reaffirmed a "buy" rating and set a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. JMP Securities increased their price target on Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. raised Precigen from an "underweight" rating to a "neutral" rating in a research report on Friday, August 15th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $8.25.

Precigen Trading Down 8.5%

Shares of NASDAQ PGEN opened at $3.79 on Monday. The stock has a fifty day simple moving average of $2.73 and a two-hundred day simple moving average of $1.93. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $5.22. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -9.02 and a beta of 1.82.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.67 million. Analysts forecast that Precigen, Inc. will post -0.32 EPS for the current year.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.